United States - English - NLM (National Library of Medicine)

conju korea inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - purpose: anti wrinkle uses: shape memory lifting cream having the feature of returning to its original shape by itself. intensively working on aged skin due to wrinkles & loss of elasticity, and then fostering tight skin in a short time.

United States - English - NLM (National Library of Medicine)

conju korea inc. - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - purpose: skin protectant uses: intensive moisture cream supplying moisture to the dry skin in a short time. containing three natural water harvested from nature with excellent human body affinity: hot spring water, deep sea water and glacier water, supplying sufficient moisture & nutrition to the dry and barren skin

United States - English - NLM (National Library of Medicine)

conju korea inc. - mineral oil (unii: t5l8t28fgp) (mineral oil - unii:t5l8t28fgp) - purpose: skin protectant uses: naturalism cleansing balm containing 9 vegetable oil. soft & fine particles remove even the hidden wastes of the skin meticulously, while 4 types of lotus extracts prescribed with it provide moisture after cleansing.

United States - English - NLM (National Library of Medicine)

conju korea inc. - dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o) - purpose: skin protectant uses: essence with high concentration supplying immediate moisture & nutrition to the skin. finer particles than pores supply moisture & nutrition to the dried skin immediately, indicate outstanding efficacy for soothing the sensitive skin with speedy skin placating function.

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.625mg - conjugated estrogens 0.625mg - estrogens

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 1.25mg - conjugated estrogens 1.25mg - estrogens

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.3mg - conjugated estrogens 0.3mg - estrogens

Canada - English - Health Canada

pharmascience inc - conjugated estrogens - tablet - 0.9mg - conjugated estrogens 0.9mg - estrogens

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.625 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; carnauba wax; sucrose; hypromellose; lactose monohydrate; macrogol 400; hyprolose; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; allura red ac aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1 premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.